Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 2, 2004, Pages 173-180

  Bernard, Bert ^a   Capello, Astrid ^a   Van Hagen, Martin ^a   Breeman, Wout ^a   Srinivasan, Ananth ^b   Schmidt, Michelle ^b   Erion, Jack ^b   Van Gameren, Arthur ^a   Krenning, Eric ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

Radionuclide therapy; RGD; RGD DTPA Tyr3 octreotate; Scintigraphy; Tyr3 octreotate

Indexed keywords

OCTREOTIDE[3 TYROSINE]; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; OCTREOTIDE[3 TYROSINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; OCTREOTIDE[3 TYROSINE] ARGINYLGLYCYLASPARTYL PENTETATE INDIUM IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; ISOTOPE LABELING; MALE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; RADIOISOTOPE THERAPY; RAT;

ANIMALS; CELL LINE, TUMOR; INDIUM RADIOISOTOPES; NEOPLASMS; OLIGOPEPTIDES; PENTETIC ACID; PEPTIDES, CYCLIC; RATS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; TISSUE DISTRIBUTION;

EID: 2542420713     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804323071940     Document Type: Conference Paper

References (13)

1. Reubi JC, Laissue J, Krenning EP, et al. Somatostatin receptors in human cancer: Incidence, characterics, functional correlates, and clinical implications. J Steroid Biochem Mol Biol 1992;43:27.
2. 3]octreotide: The rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716.
3. De Jong M, Kwekkeboom D, Valkema R, et al. Radiolabeled peptides for tumor therapy: Current status and future directions. Plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging 2003;30:463.
4. De Jong M, Breeman WA, Bakker WH, et al. Comparison of (111)In-labeled somatostatin analogs for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437.
5. 0] octreotide in patients. Eur J Nucl Med 2001;28:1319.
6. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001;12:355.
7. Haubner R, Wester HJ, Burkhart F, et al. Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med 2001;42:326.
8. Van Hagen PM, Breeman WAP, Bernard BF, et al. Evaluation of a radiolabeled cyclic DTPA-RGD analog for tumor imaging and radionuclide therapy. Int J Cancer 2000;90:186.
9. Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002;62:6146.
10. Buckley CD, Pilling D, Henriquez NV, et al. RGD-peptides induce apoptosis by direct caspase-3 activation. Nature 1999;397:534.
11. Bernard BF, Krenning EP, Breeman WAP, et al. Use of the rat pancreatic CA20948 cell line for the comparison of radiolabeled peptides for receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Comm 2000;21:1079.
12. 3]octreotide: Peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Comm 1998;19:238.
13. Capello A, Breeman WAP, Bernard BF, et al. RGD-DTPA-octreotate for radionuclide therapy of somatostatin receptor-positive tumours. Eur J Nucl Med 2002;29:119.